TLX Stock Summary and Trading Ideas (Telix Pharmaceuticals Limited - American Depositary Shares | NASDAQ:TLX)

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Telix Pharmaceuticals Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol TLX.

As of December 19, 2025, TLX stock price declined to $7.80 with 194,252 million shares trading.

TLX has a beta of 1.76, meaning it tends to be more sensitive to market movements. TLX has a correlation of 0.24 to the broad based SPY ETF.

TLX has a market cap of $2.61 billion. This is considered a Mid Cap stock.

TLX has underperformed the market in the last year with a price return of -52.3% while the SPY ETF gained +18.1%. TLX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.8% and -20.8%, respectively, while the SPY returned +2.8% and -0.5%, respectively.

TLX support price is $7.56 and resistance is $8.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TLX shares will trade within this expected range on the day.